The haemostatic effect of deep-frozen platelets versus room temperature-stored platelets in the treatment of surgical bleeding: MAFOD-study protocol for a randomized controlled non-inferiority trial

Tim W H Rijnhout, Femke Noorman, Robert A van der Horst, Edward C T H Tan, Victor V A Viersen, Oscar J F van Waes, Leo M G van de Watering, B L S Borger van der Burg, Jaap J Zwaginga, Michael H J Verhofstad, Rigo Hoencamp, Tim W H Rijnhout, Femke Noorman, Robert A van der Horst, Edward C T H Tan, Victor V A Viersen, Oscar J F van Waes, Leo M G van de Watering, B L S Borger van der Burg, Jaap J Zwaginga, Michael H J Verhofstad, Rigo Hoencamp

Abstract

Background: The Netherlands Armed Forces have been successfully using deep-frozen (- 80 °C) thrombocyte concentrate (DTC) for the treatment of (massive) bleeding trauma patients in austere environments since 2001. However, high-quality evidence for the effectiveness and safety of DTCs is currently lacking. Therefore, the MAssive transfusion of Frozen bloOD (MAFOD) trial is designed to compare the haemostatic effect of DTCs versus room temperature-stored platelets (RSP) in the treatment of surgical bleeding.

Methods: The MAFOD trial is a single-blinded, randomized controlled non-inferiority trial and will be conducted in three level 1 trauma centres in The Netherlands. Patients 12 years or older, alive at hospital presentation, requiring a massive transfusion including platelets and with signed (deferred) consent will be included. The primary outcome is the percentage of patients that have achieved haemostasis within 6 h and show signs of life. Haemostasis is defined as the time in minutes from arrival to the time of the last blood component transfusion (plasma/platelets or red blood cells), followed by a 2-h transfusion-free period. This is the first randomized controlled study investigating DTCs in trauma and vascular surgical bleeding.

Discussion: The hypothesis is that the percentage of patients that will achieve haemostasis in the DTC group is at least equal to the RSP group (85%). With a power of 80%, a significance level of 5% and a non-inferiority limit of 15%, a total of 71 patients in each arm are required, thus resulting in a total of 158 patients, including a 10% refusal rate. The data collected during the study could help improve the use of platelets during resuscitation management. If proven non-inferior in civilian settings, frozen platelets may be used in the future to optimize logistics and improve platelet availability in rural or remote areas for the treatment of (massive) bleeding trauma patients in civilian settings.

Trial registration: ClinicalTrials.gov NCT05502809. Registered on 16 August 2022.

Keywords: Bleeding; Blood; Coagulopathy; Cryopreservation; Haemorrhage; Injury; Platelets; Resuscitation; Transfusion; Trauma.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
SPIRIT schedule of enrolment, interventions and assessments
Fig. 2
Fig. 2
Preparation of deep-frozen platelets

References

    1. Eastridge BJ, Holcomb JB, Shackelford S. Outcomes of traumatic hemorrhagic shock and the epidemiology of preventable death from injury. Transfusion. 2019;59(S2):1423–1428. doi: 10.1111/trf.15161.
    1. Eastridge BJ, Mabry RL, Seguin P, Cantrell J, Tops T, Uribe P, et al. Death on the battlefield (2001-2011): implications for the future of combat casualty care. J Trauma Acute Care Surg. 2012;73(6 Suppl 5):S431–S437. doi: 10.1097/TA.0b013e3182755dcc.
    1. Geeraedts LM, Jr, Pothof LA, Caldwell E, de Lange-de Klerk ES, D’Amours SK. Prehospital fluid resuscitation in hypotensive trauma patients: do we need a tailored approach? Injury. 2015;46(1):4–9. doi: 10.1016/j.injury.2014.08.001.
    1. Holcomb JB, Tilley BC, Baraniuk S, Fox EE, Wade CE, Podbielski JM, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. Jama. 2015;313(5):471–482. doi: 10.1001/jama.2015.12.
    1. Lelkens CC, Koning JG, de Kort B, Floot IB, Noorman F. Experiences with frozen blood products in the Netherlands military. Transfus Apher Sci. 2006;34(3):289–298. doi: 10.1016/j.transci.2005.11.008.
    1. Noorman F, Rijnhout TWH, Zoodsma M, Hoencamp R. 80 °C deep frozen erythrocytes during military operations. The Dutch frozen concept. Transfus Apher Sci. 2020;59(3):102789. doi: 10.1016/j.transci.2020.102789.
    1. Noorman F, van Dongen TT, Plat MJ, Badloe JF, Hess JR, Hoencamp R. Transfusion: -80 degrees C frozen blood products are safe and effective in military casualty care. PLoS One. 2016;11(12):e0168401. doi: 10.1371/journal.pone.0168401.
    1. Holley A, Marks DC, Johnson L, Reade MC, Badloe JF, Noorman F. Frozen blood products: clinically effective and potentially ideal for remote Australia. Anaesth Intensive Care. 2013;41(1):10–19. doi: 10.1177/0310057X1304100104.
    1. Khuri SF, Healey N, MacGregor H, Barnard MR, Szymanski IO, Birjiniuk V, et al. Comparison of the effects of transfusions of cryopreserved and liquid-preserved platelets on hemostasis and blood loss after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1999;117(1):172–183. doi: 10.1016/S0022-5223(99)70483-6.
    1. Slichter SJ, Dumont LJ, Cancelas JA, Jones M, Gernsheimer TB, Szczepiorkowski ZM, et al. Safety and efficacy of cryopreserved platelets in bleeding patients with thrombocytopenia. Transfusion. 2018;58(9):2129–2138. doi: 10.1111/trf.14780.
    1. Kleinveld DJB, Juffermans NP, Noorman F. The use of frozen platelets for the treatment of bleeding. In: Vincent J-L, editor. Annual Update in Intensive Care and Emergency Medicine 2020. Cham: Springer International Publishing; 2020. pp. 317–329.
    1. Kleinveld DJB, Sloos PH, Noorman F, Maas MAW, Kers J, Rijnhout TWH, et al. The use of cryopreserved platelets in a trauma-induced hemorrhage model. Transfusion. 2020;60(9):2079–2089.
    1. Baksaas-Aasen K, Gall LS, Stensballe J, Juffermans NP, Curry N, Maegele M, et al. Viscoelastic haemostatic assay augmented protocols for major trauma haemorrhage (ITACTIC): a randomized, controlled trial. Intensive Care Med. 2021;47(1):49–59. doi: 10.1007/s00134-020-06266-1.
    1. McGuinness S, Charlewood R, Gilder E, Parke R, Hayes K, Morley S, et al. A pilot randomized clinical trial of cryopreserved versus liquid-stored platelet transfusion for bleeding in cardiac surgery: the cryopreserved versus liquid platelet-New Zealand pilot trial. Vox Sang. 2022;117(3):337–345. doi: 10.1111/vox.13203.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다